Despite these outcomes, CTLA‐4 inhibitors have shown limited efficacy in BC and are associated with severe immune‐related adverse effects, partly linked to the lysosomal degradation of CTLA‐4 [611]. This evidence concerns the gene CTLA4 and breast cancer.